gefitinib has been researched along with cvt 313 in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (cvt 313) | Trials (cvt 313) | Recent Studies (post-2010) (cvt 313) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 19 | 0 | 11 |
| Protein | Taxonomy | gefitinib (IC50) | cvt 313 (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 2.3 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 3.7 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 3.7 | |
| Cyclin-A2 | Homo sapiens (human) | 0.22 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.176 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.198 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 9.2 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 2.3 | |
| Cyclin-H | Homo sapiens (human) | 9.2 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 9.2 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.419 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.419 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Dai, L; Hu, ZD; Li, XL; Sun, YX; Tao, YF; Wang, AM; Wang, SP; Wu, Q; Yang, AL; Zhang, J | 1 |
2 other study(ies) available for gefitinib and cvt 313
| Article | Year |
|---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bufanolides; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin-Dependent Kinase 2; Down-Regulation; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Hep G2 Cells; Humans; Liver Neoplasms; M Phase Cell Cycle Checkpoints; Network Pharmacology; Protein Interaction Maps; Protein Kinase Inhibitors; Purines; Signal Transduction | 2021 |